DouYu International Holdings Limited - ADS (DOYU) News
Filter DOYU News Items
DOYU News Results
|Loading, please wait...|
DOYU News Highlights
- DOYU's 30 day story count now stands at 2.
- Over the past 21 days, the trend for DOYU's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about DOYU are APRE, AVCT and RWLK.
Latest DOYU News From Around the Web
Below are the latest news stories about DouYu International Holdings Ltd that investors may wish to consider to help them evaluate DOYU as an investment opportunity.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 37% to $1.78 in pre-market trading after declining around 4% on Monday. ReWalk Robotics, last month, reported Q2 sales of $1.44 million. Aprea Therapeutics, Inc. (NASDAQ: APRE) rose 15.1% to $5.58 in pre-market trading after the company announced it presented data from the Phase 1/2 trial of eprenetapopt in advanced solid tumors at ESMO Congress 2021. American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) rose 14.1% to $3.23 in pre-market tradin
Good morning, trader!
Gainers Cardiff Oncology, Inc. (NASDAQ: CRDF) rose 17.3% to $8.27 in pre-market trading after the company announced new data from its Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer showing "robust objective response rate and progression free survival." TSR, Inc. (NASDAQ: TSRI) rose 15.7% to $12.82 in pre-market trading. The company, last month, said it swung to a quarterly loss. Gold Royalty Corp. (NYSE: GROY) rose 15.1% to $4.74 in pre-market trading. Gold Royalty, Abitibi Royalt
(RTTNews) - DouYu International Holdings Limited (DOYU) said its board has authorized a share repurchase program. Under the program, the company is authorized to repurchase up to $100 million of its ordinary shares in the form of American depositary shares during a period of up to 12 months beginning August 30, 2021. DouYu plans to use the
DouYu International Holdings Limited ("DouYu" or the "Company") (Nasdaq: DOYU), a leading game-centric live streaming platform in China and a pioneer in the eSports value chain, today announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$100 million of its ordinary shares in the form of American depositary shares during a period of up to 12 months commencing on August 30, 2021, subject to the relevant rules under the Secur
(Bloomberg) -- Tencent Holdings Ltd. has begun re-deploying people and resources toward its own game streaming platform, after China blocked a merger that would have cemented the social media giant’s lead in a $3 billion sector.Tencent proposed combining investees Huya Inc. and DouYu International Holdings Ltd. -- China’s two biggest Twitch-like services -- in 2020, but the country’s antitrust watchdog rejected the deal in July after Beijing stepped up scrutiny of big tech. Now, Tencent has set
Gainers Triple-S Management Corporation (NYSE: GTS) shares jumped 45.3% to $35.15. GuideWell Mutual Holding Corporation, parent of Blue Cross and Blue Shield of Florida Inc, will acquire Triple-S Management for an equity value of approximately $900 million. Takung Art Co., Ltd. (NASDAQ: TKAT) gained 37.5% to $7.56. KLX Energy Services Holdings, Inc. (NASDAQ: KLXE) surged 29.6% to $7.48. KLX Energy Services is expected to release its Q2 financial results on Thursday, September 9, 2021. SkyWater T
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) rose 48.3% to $0.777 in pre-market trading after gaining over 3% on Monday. The company, earlier during the month, reported downbeat quarterly results. Cara Therapeutics, Inc. (NASDAQ: CARA) rose 26.7% to $18.09 in pre-market trading. Vifor Pharma and Cara Therapeutics reported the US FDA approval of KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialys
View more earnings on DOYUSee more from BenzingaClick here for options trades from BenzingaTikTok Fever Catches On An Unusual Player After Facebook, SnapWhy Do Analysts See Upside Potential In CyberArk?© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.